ATNX News and Press, Athenex Inc. From 05/10/22

Athenex press release (NASDAQ:ATNX): Q1 GAAP EPS of -$0.16 beats by $0.03. Revenue of $29.7M (-27.6% Y/Y) beats by $4.28M. FY22 Guidance: Athenex now expects product sales growth to be in the range of 20-25% over the prior year period, versus the prior range of 15-20% growth, year-over-year, ...

Reports 1Q product sales of $29.0M, up 42% year-over-year Encouraging interim update from ANCHOR study of KUR-502 presented at ASTCT with 60% overall response rate (ORR) and 6-month complete response (CR) rate of 29% in the NHL cohort Abstract for KUR-501 in GINAKIT2 stu...

Data presented by investigators from the Texas Children’s Cancer Center’s Center for Advanced Innate Cell Therapy and Baylor College of Medicine Data demonstrate expansion of CAR-NKT cells post-transfer in all patients, and objective responses in patients with rela...

BUFFALO, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provid...

Athenex (NASDAQ:ATNX) reported data from a phase 1 trial of KUR-502 (Allogeneic CD19 CAR-NKT Cells) to treat patients with non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). The company said NKT cells were isolated from the leukapheresis product of one HLA-unmatched ...

Interim analysis provides response data from 7 evaluable patients including two additional patients, one with non-Hodgkin lymphoma (NHL) and one with acute lymphoblastic leukemia (ALL) Six-month CR rate of 29%, including 1 ongoing CR at 34 weeks in heavily pretreated patients ...

Athenex Inc. (NASDAQ:ATNX) traded at a new 52-week high today of $23.00. Approximately 91.4 million shares have changed hands today, as compared to an average 30-day volume of 900,000 shares. In the past 52 weeks, Athenex Inc. share prices are bracketed by a low of $0.73 and a high of $2...

Athenex, Inc. (ATNX) Q4 2021 Earnings Conference Call March 16, 2022, 4:30 PM ET Company Participants Johnson Lau – Chief Executive Officer Caileigh Dougherty – Investor Relations Dan Lang – President, Athenex Cell Therapy Kurt Gunter – Chief Medical Officer, Cell ...

Athenex press release (NASDAQ:ATNX): Q4 GAAP EPS of -$0.95 misses by $0.62. Revenue of $24.94M (+14.4% Y/Y) misses by $5.88M. For further details see: Athenex GAAP EPS of -$0.95 misses by $0.62, revenue of $24.94M misses by $5.88M

Buffalo, New York-based biotech Athenex (NASDAQ:ATNX) said on Wednesday that the company is implementing cost-cutting measures and monetization of non-core assets to extend the cash runway this year. Following the announcement, Athenex (ATNX) shares lost ~7% in the post-market. With...